Matches in SemOpenAlex for { <https://semopenalex.org/work/W1597151907> ?p ?o ?g. }
- W1597151907 endingPage "2158" @default.
- W1597151907 startingPage "2153" @default.
- W1597151907 abstract "SummaryCurrently, few topics in the field of anticoagulant therapy are as intensely discussed as the question: which is the best new oral anticoagulant? The most advanced substances in this field are the oral direct factor Xa‐inhibitors rivaroxaban, apixaban and edoxaban and the oral direct thrombin inhibitor dabigatran. All of these substances are currently being tested in very similar phase III trials or are in the process of approval. In these trials, open‐label or double‐blind double‐dummy designs are being used to evaluate the efficacy and safety in prevention and treatment of venous thromboembolism or stroke prevention in atrial fibrillation in several thousands of patients. As a consequence, an intense discussion of the advantages and disadvantages of open‐label or double‐blind trials is currently under way and interpretation of trial results is often focused on this matter. In general, a blinded trial is regarded as being less subject to bias than an open trial because it minimizes the impact of knowledge of treatment allocation on post‐randomized treatment decisions and on reporting of outcomes. However, a blinded trial is not always feasible. Thus, in some respects, the two trial designs offer complementary strengths and weaknesses. This review addresses the risks of bias for internal and external validity of open‐label and double‐blind anticoagulation trials to help to objectify this debate. Currently, few topics in the field of anticoagulant therapy are as intensely discussed as the question: which is the best new oral anticoagulant? The most advanced substances in this field are the oral direct factor Xa‐inhibitors rivaroxaban, apixaban and edoxaban and the oral direct thrombin inhibitor dabigatran. All of these substances are currently being tested in very similar phase III trials or are in the process of approval. In these trials, open‐label or double‐blind double‐dummy designs are being used to evaluate the efficacy and safety in prevention and treatment of venous thromboembolism or stroke prevention in atrial fibrillation in several thousands of patients. As a consequence, an intense discussion of the advantages and disadvantages of open‐label or double‐blind trials is currently under way and interpretation of trial results is often focused on this matter. In general, a blinded trial is regarded as being less subject to bias than an open trial because it minimizes the impact of knowledge of treatment allocation on post‐randomized treatment decisions and on reporting of outcomes. However, a blinded trial is not always feasible. Thus, in some respects, the two trial designs offer complementary strengths and weaknesses. This review addresses the risks of bias for internal and external validity of open‐label and double‐blind anticoagulation trials to help to objectify this debate." @default.
- W1597151907 created "2016-06-24" @default.
- W1597151907 creator A5004003194 @default.
- W1597151907 creator A5042290277 @default.
- W1597151907 date "2011-11-01" @default.
- W1597151907 modified "2023-10-10" @default.
- W1597151907 title "External and internal validity of open label or double‐blind trials in oral anticoagulation: better, worse or just different?" @default.
- W1597151907 cites W1972328044 @default.
- W1597151907 cites W1979703196 @default.
- W1597151907 cites W2000366380 @default.
- W1597151907 cites W2000669270 @default.
- W1597151907 cites W2030084116 @default.
- W1597151907 cites W2033890227 @default.
- W1597151907 cites W2063464618 @default.
- W1597151907 cites W2090225839 @default.
- W1597151907 cites W2097854437 @default.
- W1597151907 cites W2115787552 @default.
- W1597151907 cites W2118092611 @default.
- W1597151907 cites W2136489990 @default.
- W1597151907 cites W2139511461 @default.
- W1597151907 cites W2145036036 @default.
- W1597151907 cites W2270113861 @default.
- W1597151907 cites W4322700969 @default.
- W1597151907 cites W4376860442 @default.
- W1597151907 doi "https://doi.org/10.1111/j.1538-7836.2011.04507.x" @default.
- W1597151907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21920015" @default.
- W1597151907 hasPublicationYear "2011" @default.
- W1597151907 type Work @default.
- W1597151907 sameAs 1597151907 @default.
- W1597151907 citedByCount "52" @default.
- W1597151907 countsByYear W15971519072012 @default.
- W1597151907 countsByYear W15971519072013 @default.
- W1597151907 countsByYear W15971519072014 @default.
- W1597151907 countsByYear W15971519072015 @default.
- W1597151907 countsByYear W15971519072016 @default.
- W1597151907 countsByYear W15971519072017 @default.
- W1597151907 countsByYear W15971519072018 @default.
- W1597151907 countsByYear W15971519072019 @default.
- W1597151907 countsByYear W15971519072020 @default.
- W1597151907 countsByYear W15971519072021 @default.
- W1597151907 countsByYear W15971519072022 @default.
- W1597151907 countsByYear W15971519072023 @default.
- W1597151907 crossrefType "journal-article" @default.
- W1597151907 hasAuthorship W1597151907A5004003194 @default.
- W1597151907 hasAuthorship W1597151907A5042290277 @default.
- W1597151907 hasBestOaLocation W15971519071 @default.
- W1597151907 hasConcept C126322002 @default.
- W1597151907 hasConcept C142724271 @default.
- W1597151907 hasConcept C15744967 @default.
- W1597151907 hasConcept C174106493 @default.
- W1597151907 hasConcept C177713679 @default.
- W1597151907 hasConcept C204787440 @default.
- W1597151907 hasConcept C27081682 @default.
- W1597151907 hasConcept C2776301958 @default.
- W1597151907 hasConcept C2778661090 @default.
- W1597151907 hasConcept C2778810321 @default.
- W1597151907 hasConcept C2779161974 @default.
- W1597151907 hasConcept C2780290652 @default.
- W1597151907 hasConcept C2780638905 @default.
- W1597151907 hasConcept C2991744798 @default.
- W1597151907 hasConcept C535046627 @default.
- W1597151907 hasConcept C71924100 @default.
- W1597151907 hasConcept C77805123 @default.
- W1597151907 hasConceptScore W1597151907C126322002 @default.
- W1597151907 hasConceptScore W1597151907C142724271 @default.
- W1597151907 hasConceptScore W1597151907C15744967 @default.
- W1597151907 hasConceptScore W1597151907C174106493 @default.
- W1597151907 hasConceptScore W1597151907C177713679 @default.
- W1597151907 hasConceptScore W1597151907C204787440 @default.
- W1597151907 hasConceptScore W1597151907C27081682 @default.
- W1597151907 hasConceptScore W1597151907C2776301958 @default.
- W1597151907 hasConceptScore W1597151907C2778661090 @default.
- W1597151907 hasConceptScore W1597151907C2778810321 @default.
- W1597151907 hasConceptScore W1597151907C2779161974 @default.
- W1597151907 hasConceptScore W1597151907C2780290652 @default.
- W1597151907 hasConceptScore W1597151907C2780638905 @default.
- W1597151907 hasConceptScore W1597151907C2991744798 @default.
- W1597151907 hasConceptScore W1597151907C535046627 @default.
- W1597151907 hasConceptScore W1597151907C71924100 @default.
- W1597151907 hasConceptScore W1597151907C77805123 @default.
- W1597151907 hasIssue "11" @default.
- W1597151907 hasLocation W15971519071 @default.
- W1597151907 hasLocation W15971519072 @default.
- W1597151907 hasOpenAccess W1597151907 @default.
- W1597151907 hasPrimaryLocation W15971519071 @default.
- W1597151907 hasRelatedWork W1969889370 @default.
- W1597151907 hasRelatedWork W1985700561 @default.
- W1597151907 hasRelatedWork W1991822753 @default.
- W1597151907 hasRelatedWork W2017559285 @default.
- W1597151907 hasRelatedWork W2186954303 @default.
- W1597151907 hasRelatedWork W2385945324 @default.
- W1597151907 hasRelatedWork W2518797397 @default.
- W1597151907 hasRelatedWork W2731035403 @default.
- W1597151907 hasRelatedWork W2794174617 @default.
- W1597151907 hasRelatedWork W2796082272 @default.
- W1597151907 hasVolume "9" @default.
- W1597151907 isParatext "false" @default.
- W1597151907 isRetracted "false" @default.